Get inside Wall Road with StreetInsider Premium. Declare your 1-week free trial here.
Presentation from Summary to be Delivered on the Southern Affiliation of Vascular Surgical procedure Convention January eight to 11 in Palm Seaside, Florida
IRVINE, CA / ACCESSWIRE / December 20, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI)(NASDAQ: HJLIW), a developer of medical gadgets that restore cardiac and vascular well being, introduced as we speak that an summary entitled Outcomes of First-in-Human Implantation of a Prosthetic Venous Valve has been revealed within the January 2020 version of the Journal of Vascular Surgical procedure®. A presentation from the summary will probably be delivered by Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI’s first-in-man VenoValve examine in Bogota, Colombia, on the 44th Annual Assembly of the Southern Affiliation for Vascular Surgical procedure (“SAVS”), which is able to happen January eight to January 11 in Palm Seaside, Florida.
Robert Berman, Hancock Jaffe’s Chief Govt Officer acknowledged, “We’re pleased with Dr. Marc Glickman, our Senior Vice President and Chief Medical Officer, in addition to the remainder of our medical staff, for the worldwide consideration we’re receiving on our floor breaking work with the VenoValve. Along with the honors talked about above, the summary from the Journal of Vascular Surgical procedure was featured in a bi-weekly information replace e mail despatched out by the American School of Surgeons to its greater than 82,000 members. Our success with the VenoValve continues to be of intense curiosity to the vascular and surgical communities.”
Persistent Venous Insufficiency (“CVI”) happens when valves within the veins of the leg fail, inflicting blood to circulation backwards (reflux) and pool within the decrease extremities. The pooling of blood causes elevated strain within the veins of the leg, often called venous hypertension. CVI of the deep venous system is a debilitating situation that usually contains leg swelling, debilitating ache, and in extreme situations, open sores often called venous ulcers.
HJLI has implanted VenoValves in 10 CVI sufferers as a part of its first-in-man trial in Colombia. On October 24, 2019, six-month information for the trial was offered on the primary 5 sufferers that acquired VenoValves, which confirmed important enhancements in all examine endpoints, minimal issues of safety, and dramatic enchancment and therapeutic of venous ulcers.
Roughly 2.four million individuals within the U.S. endure from CVI resulting from reflux within the deep venous system. Estimates point out that direct medical prices from CVI within the U.S. exceed $30 Billion per 12 months. There are at present no FDA permitted gadgets or efficient therapies for deep venous CVI.
The Journal of Vascular Surgical procedure® is devoted to the science and artwork of vascular surgical procedure, aiming to be the premier worldwide journal of medical, endovascular and surgical care of vascular illnesses. Because the first problem was launched in 1984, the objective of the journal has been to enhance the administration of sufferers with vascular illnesses by publishing related papers that report vital medical, surgical and endovascular advances, take a look at new hypotheses, and handle present controversies.
The Southern Affiliation of Vascular Surgical procedure was established to advertise the artwork and science of vascular surgical procedure and to additional schooling within the complete care of vascular illness, together with issues of the arteries, veins, lymphatics and microcirculation unique of the guts and mind. The SAVS covers the areas of Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, South Carolina, Tennessee, Texas, Virginia, West Virginia and Washington D.C. The Affiliation is broadly thought of among the many most established and vibrant regional vascular organizations in the USA. The 44th Annual Assembly of the Southern Affiliation of Vascular Surgical procedure will probably be held January eight – 11, 2020 at The Breakers Palm Seaside in Palm Seaside, Florida
About Hancock Jaffe Laboratories, Inc.
Hancock Jaffe Laboratories (NASDAQ: HJLI) makes a speciality of growing and manufacturing bioprosthetic (tissue primarily based) medical gadgets to ascertain improved requirements of look after treating cardiac and vascular illnesses. Hancock Jaffe at present has two lead product candidates: the VenoValve®, a porcine primarily based valve which is meant to be surgically implanted within the deep venous system of the leg to deal with reflux related to Persistent Venous Insufficiency; and the CoreoGraft®, a bovine tissue primarily based off the shelf conduit supposed for use for coronary artery bypass surgical procedure. Hancock Jaffe has a 20-year historical past of growing and producing FDA permitted medical gadgets that maintain or help life. The present administration staff at Hancock Jaffe has been related to over 80 FDA or CE marked medical gadgets. For extra data, please go to HancockJaffe.com.
Cautionary Word on Ahead-Trying Statements
This press launch and any statements of stockholders, administrators, workers, representatives and companions of Hancock Jaffe Laboratories, Inc. (the “Firm”) associated thereto comprise, or could comprise, amongst different issues, sure “forward-looking statements” inside the which means of the Personal Securities Litigation Reform Act of 1995. Such forward-looking statements contain important dangers and uncertainties. Such statements could embody, with out limitation, statements recognized by phrases corresponding to “tasks,” “could,” “will,” “might,” “would,” “ought to,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or comparable expressions. These statements are primarily based upon the present beliefs and expectations of the Firm’s administration and are topic to important dangers and uncertainties, together with these detailed within the Firm’s filings with the Securities and Change Fee. Precise outcomes (together with, with out limitation, the efficiency of the brand new board members described herein) could differ considerably from these set forth or implied within the forward-looking statements. These forward-looking statements contain sure dangers and uncertainties which might be topic to vary primarily based on varied elements (lots of that are past the Firm’s management). The Firm undertakes no obligation to publicly replace any forward-looking statements, whether or not because of new data, future displays or in any other case, besides as required by relevant legislation.
HJLI Press Contacts:
SOURCE: Hancock Jaffe Laboratories, Inc.
View supply model on accesswire.com: